Key result
A novel multiple antigen peptide vaccine (B2T-TB2) elicited higher B- and T-cell specific responses than former candidates in swine, with immunization scores remaining stable after 4 months.
Why the study?
A broadly protective and biosafe vaccine against foot-and-mouth disease virus remains an unmet need in the animal health sector.
Does the B2T-TB2 dendrimeric peptide vaccine elicit higher B- and T-cell specific responses against foot-and-mouth disease virus compared to former candidates in swine?
Does the B2T-TB2 dendrimeric peptide vaccine elicit higher B- and T-cell specific responses against foot-and-mouth disease virus compared to former candidates in swine?
A novel dendrimeric peptide-based vaccine (B2T-TB2) elicits strong and stable B- and T-cell immune responses against foot-and-mouth disease virus in swine at a reduced dose.
May inform FMDV vaccine design in swine; leaves open translation to livestock efficacy and safety trials.
A broadly protective and biosafe vaccine against foot-and-mouth disease virus (FMDV) remains an unmet need in the animal health sector. We have previously reported solid protection against serotype O FMDV afforded by dendrimeric peptide structures harboring virus-specific B- and T-cell epitopes, and also shown such type of multivalent presentations to be advantageous over simple B-T-epitope linear juxtaposition. Chemically, our vaccine platforms are modular constructions readily made from specified B- and T-cell epitope precursor peptides that are conjugated in solution. With the aim of developing an improved version of our formulations to be used for on-demand vaccine applications, we evaluate in this study a novel design for epitope presentation to the immune system based on a multiple antigen peptide (MAP) containing six immunologically relevant motifs arranged in dendrimeric fashion (named B2T-TB2). Interestingly, two B2T units fused tail-to-tail into a single homodimer platform elicited higher B- and T-cell specific responses than former candidates, with immunization scores remaining stable even after 4 months. Moreover, this macromolecular assembly shows consistent immune response in swine, the natural FMDV host, at reduced dose. Thus, our versatile, immunogenic prototype can find application in the development of peptide-based vaccine candidates for various therapeutic uses using safer and more efficacious vaccination regimens.
No takes yet. Share an insight, caveat, or question.
Defaus et al. (2020) studied Foot-and-mouth disease virus (FMDV). B2T-TB2 multiple antigen peptide vaccine vs. Former vaccine candidates was evaluated on B- and T-cell specific responses. A novel multiple antigen peptide vaccine (B2T-TB2) elicited higher B- and T-cell specific responses than former candidates in swine, with immunization scores remaining stable after 4 months.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: